Politico April 8, 2024
Alphabet health company Verily and pharmaceutical brand Otsuka are embarking on a multiyear study using artificial intelligence to better understand and support people with mental health conditions.
Verily is enrolling 500 subjects with symptoms of depression in its digital clinical trial.
The study’s main goal is to understand the real-world effects of treatment at the onset of symptoms. Participants will regularly share how they’re feeling via self-assessments. But Verily’s chief science officer, Andrew Trister, said he’d eventually like to include more tangible data points like digital biomarkers.
“Leveraging phones and, say, wearables that have different sensors on them, can we make some sort of inference about what’s happening with the person in this remote model because we have a continuous...
Today's Sponsors
Today's Sponsor